Tenepride M Tablets (Teneligliptin + Metformin )

• Composition :
  Each film coated tablet contains Teneligliptin 20 mg and Metformin Hydrochloride (as sustained release) 500/1000mg.
• Indications :
  Tenepride M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• Pharmacodynamics :
  Teneligliptin is a DPP-4 inhibitor, exert its actions slowing the inactivation of incretin hormones. By increasing and prolonging active incretin levels, teneligliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Metformin is a biguanideantihyperglycemic agent used for treating diabetes mellitus. Metformin decreases blood glucose levels by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
• Dosage and administration :
  The usual dosage is orally once daily or as recommended by physician.
• Contraindications :
  Contraindicated in patients with known hypersensitivity to the drug. Severe ketosis, diabetic coma or history of diabetic coma, type 1 diabetic patients. Renal impairment.
• Precautions and warnings :
  Patients with advanced liver failure, congestive heart failure (NYHA category III-IV), pituitary insufficiency or adrenal insufficiency, poor nutritional state, starvation, an irregular dietary intake, or debilitating condition, intense muscle movement or excessive alcohol intake, low serum potassium, congenital prolonged QT syndrome, history of Torsades de pointes or patients using antiarrhythmic drugs (may cause QT prolongation). Temporarily discontinue in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Vitamin B12 deficiency: Monitor hematologic parameters annually.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category B. Safety and effectiveness studies have not been conducted in nursing mothers. Paediatric Use: Safety and effectiveness in children younger than 18 years of age have not been established.
• Drug interactions :
  Should be used with caution with drugs that can enhance the blood glucose lowering effect (like β blockers, MAO inhibitors, etc.) and attenuate the blood glucose lowering effect (like steroids, thyroid hormones, etc). Cationic drugs: May reduce metformin elimination. Use with caution in patients who are taking cationic medications eliminated by renal tubular secretion.
• Adverse reactions :
  The most common adverse reactions reported are abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing and palpitation, intestinal obstruction elevated liver enzymes.
• Therapy Area :
  Anti-Diabetic agents